U.S. stocks rebounded on Wednesday after falling for three straight session on Tuesday supported by strong results from blue chip companies. There are several healthcare stocks which are showing unusual moves at mid day on Wednesday.
Healthways, Inc. (NASDAQ:HWAY) popped up 20% as the company posted better than projected second quarter earnings. The company recorded net income of $5.1 million, or 15 cents a share on revenue of $170.2 million, compared to a year ago profit of $5.8 million, or 17 cents a share on revenue of $169.6 million, ahead of analysts target of 7 cents a share. Moreover, following earnings, analyst at Carroll raised price target on the stock by 30% to $13.
Eli Lilly & Co. (NYSE:LLY) surged 3.31% to $43.37 as the company reported impressive second quarter results and boosted its 2012 profit outlook as well. The company reported net income of $924 million, or 83 cents per share, compared to a year ago profit of $1.2 billion, or $1.07 per share. On an adjusted basis, the company earned 83 cents per share, topping analysts’ estimates by 6 cents. Global sales of $5.6 billion were in line with Wall Street expectations of $5.59 billion. Lilly said it now expects full-year 2012 earnings of $3.30 to $3.40 per share, excluding special items. It had previously forecast earnings of $3.15 to $3.30 per share. Shares of LLY are up 3.76% to $43.56.
Ligand Pharmaceuticals (NASDAQ:LGNG) began rise to Wednesday after the firm said its Promacta medicine will receive priority review from U.S. regulators for a new use against blood-related complications of hepatitis C. The Food and Drug Administration aims to complete priority reviews within six months, as opposed the usual 10 months for most drugs. Promacta was originally approved in 2008 for a rare condition called chronic immune thrombocytopenic purpura, in which the body attacks its own platelets. Promacta was discovered by Ligand and is marketed by London-based GlaxoSmithKline.
WellPoint, Inc. (NYSE:WLP) slumped 12.41% after the company reduced its profit estimate as it earned less than estimated by the Wall Street. The company now projects to earn $7.30 to $7.40, down from its earlier forecast of at least $7.65 per share, excluding items. Analysts have been looking for $7.76. For the second quarter, the company earned $643.6 million, or $1.94 per share, from $701.6 million or $1.89 per share a year earlier. On an adjusted basis, the company earned $2.04 a share, missing analysts’ target of $2.08 a share. Revenue grew 2 percent to $15.17 billion, about $100 million below analyst estimates.
Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) gained traction after the firm accepted delivery of two initial pre-production units of the Verisante Aura™, an innovative skin cancer detection device, from StarFish Medical Inc. The units will be used for final usability and safety testing before commercial production begins by the end of the year. The Company also continues to work closely with Clarion Medical Technologies Inc., the exclusive Canadian distributor of Aura™, in preparing for the product launch in Canada once production begins. The firm is committed to a steady and measured roll out of Aura™ into the markets where they are approved to sell their leading-edge cancer detection technology and with only a 25.8M Market cap aims to unseat MELA Sciences, Inc. (NASDAQ:MELA) 107M Market cap as the leader in the space.
The Medicines Company (NASDAQ:MDCO) added 11.71% to $25.56 after the company’s Q2 easily tops estimates this morning. Total revenue rose 13.5% Y/Y on lower SG&A costs and a jump in sales of Angiomax/Angiox international.
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.
Add this page to your favorite Social Bookmarking websites